Browse Category

NSE:AJANTPHARM News 24 December 2025

Top Stocks to Buy Today in India: ITC, Tata Steel, Dr Reddy’s, Coal India, Ajanta Pharma and More (24 December 2025)

Top Stocks to Buy Today in India: ITC, Tata Steel, Dr Reddy’s, Coal India, Ajanta Pharma and More (24 December 2025)

Mumbai, December 24, 2025: Indian equities opened with a mild uptick on Wednesday as strong US growth cues supported risk appetite, but the session stayed choppy as IT stocks weighed and holiday-thinned volumes kept moves contained. In early trade, the Nifty 50 hovered near the 26,200 zone and the Sensex was around 85,600, with most sectors edging higher even as tech stocks slipped. Reuters As the day progressed, the mood turned more cautious. By late afternoon, benchmark indices had slipped into the red, with pharma, IT and select FMCG heavyweights dragging, even as autos, healthcare and infrastructure names provided pockets

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop